Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Beta This is a new resource

Access to Hepatitis C Treatment in Medicaid

Announced on  | Last Modified on  | Project Number: OEI-BL-24-00450
Status
Active
Agency
Centers for Medicare and Medicaid Services

OBJECTIVE

Hepatitis C is a liver disease caused by the highly infectious hepatitis C virus. If untreated, hepatitis C can result in serious liver disease. In the past decade, direct-acting antiviral drugs that can cure hepatitis C within 12 weeks have revolutionized treatment. Despite their improved tolerability over previous treatments and recommended use by prominent medical associations, these hepatitis C drugs are underutilized, and the virus continues to spread. In recent years, Federal and State policymakers have attempted to improve access to hepatitis C treatment while simultaneously addressing its high cost. In Medicaid—which serves a high proportion of people with hepatitis C—some States have arranged alternative payment structures for hepatitis C drugs and removed related coverage restrictions. This study will examine the extent to which Medicaid enrollees diagnosed with chronic hepatitis C receive drug treatment in Medicaid and identify potential disparities in treatment rates.

TIMELINE

  • November 15, 2024
    Announced
  • Today
    Office of Evaluation and Inspections In-Progress
  • Est FY2026
    Estimated Fiscal Year for Project Completion
Work Plan Type
Office of Evaluation and Inspections
HHS Agencies
Centers for Medicare and Medicaid Services
Issue Areas
Prescription Drug
Target Groups
-
Financial Groups
Medicaid